Overview

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2029-05-02
Target enrollment:
Participant gender:
Summary
The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease
Phase:
PHASE2
Details
Lead Sponsor:
Novartis Pharmaceuticals